SPY408.32+8.23 2.06%
DIA327.10+4.32 1.34%
IXIC11,984.52+321.73 2.76%

AstraZeneca beats quarterly estimates, maintains forecasts

AstraZeneca beats quarterly estimates, maintains forecasts

reuters.com · 04/29/2022 02:08
AstraZeneca beats quarterly estimates, maintains forecasts

- Pharma blue chip AstraZeneca AZN.L on Friday topped analysts' expectations for first-quarter profit and stood by its forecasts for 2022, as newer therapies for cancer, kidney disease and rare conditions made up for a decline in COVID-19 vaccine sales.


Very small blood clot risk after first AstraZeneca COVID shot - UK studies nL4N2UW3BU

FACTBOX-Front runners in development of antibody drugs against COVID-19nL8N2R81NW

UPDATE 2-AstraZeneca COVID drug neutralises Omicron sub-variants in lab studynL3N2VO15V

UPDATE 1-AstraZeneca ready to scrap plans for U.S. approval of COVID shot - FTnL3N2VK3QT

(Reporting by Pushkala Aripaka in Bengaluru and Natalie Grover in London; editing by John Stonestreet)

((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; Mobile: +91 852 751 3793;))